Calidi Biotherapeutics, Inc.

Stage 4 · Declining · week 58

As of Oct 22, 2026, Calidi Biotherapeutics is in Stage 4, the downtrend phase, now in week 58 (since Aug 28, 2025). It closed at $0.65, 97.6% below its 52-week high and below its 200-day average, which is falling.

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. More about the company

$0.65

-15.36% today

$2.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CLDI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 63w

S4 26w

S4 60w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 1w → S4 63w → S1 10w → S4 26w → S1 5w → S4 60w current

Total tracked: 166 weeks across 7 stage runs.

CLDI among Biotechnology538th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…538	CLDICalidi Biotherapeutics, Inc.	Stage 4 · wk 58	4	−40.4%

vs 52W High

-97.6%

$0.65 lo$26.56 hi

97.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 58

1w13w26w

Week 58, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-86.9%

200 DMA: $4.96 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.33x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-40.4%

-59.4%

-81.5%

YTD

-96.6%

-97.3%

Scan Membership

Breakout Watch

Latest: 2022-08-17

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 58 · Vol 1.33x

2026-10-21S4

Wk 58 · Vol 0.46x

2026-10-20S4

Wk 58 · Vol 0.19x

2026-10-19S4

Wk 58 · Vol 0.39x

2026-10-16S4

Wk 58 · Vol 0.24x

2026-10-15S4

Wk 57 · Vol 0.16x

2026-10-14S4

Wk 57 · Vol 0.34x

2026-10-13S4

Wk 57 · Vol 0.40x

2026-10-12S4

Wk 57 · Vol 0.32x

2026-10-09S4

Wk 57 · Vol 0.11x

2026-10-08S4

Wk 56 · Vol 0.11x

2026-10-07S4

Wk 56 · Vol 0.30x

Moving averages & range

50 DMA

$1.16

200 DMA

$4.96

52W High

$26.56

52W Low

$0.65

5D Low

$0.65

Resistance levels (recent highs)

20d High

$1.13

60d High

$1.89

120d High

$3.52

250d High

$26.56

Next resistance

+73.8%

to 20d High

ROE

-672.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.4

Calidi Biotherapeutics: quick answers

What stage is Calidi Biotherapeutics in?

As of Oct 22, 2026, Calidi Biotherapeutics (CLDI) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 28, 2025 and is in week 58. What the four stages mean

Is Calidi Biotherapeutics in an uptrend?

No. Calidi Biotherapeutics is in a Stage 4 downtrend. It trades 86.9% below its 200-day average, which is falling.

How far is Calidi Biotherapeutics from its 52-week high?

Calidi Biotherapeutics closed at $0.65 on Oct 22, 2026, 97.6% below its 52-week high of $26.56. Its 52-week low is $0.65.

How has Calidi Biotherapeutics performed over the past year?

As of Oct 22, 2026, Calidi Biotherapeutics is down 97.3% over the past year and down 96.6% so far in 2026.

Which sector and industry is Calidi Biotherapeutics in?

Calidi Biotherapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.